Categories
Change Password!
Reset Password!
Due to the remarkable
efficacy of GnRH-antagonists for the management of moderate to severe pain
associated with endometriosis, the Elagolix got FDA approval.
A newly published
study in the Journal of Expert Opinion on Biological Therapy highlights the
recent developments in the setting of endometriosis management. In the latest
investigations, it was found that some of the females experience partial or no
reduction in pain or its recurrence after the discontinuation of treatments
like combined hormonal contraceptives and progestins, which are currently
present as the first-line treatments for endometriosis. This is why new
medications or treatments are needed for endometriosis management.
The most promising
results regarding endometriosis treatment were shown by the aromatase
inhibitors (AIs) and gonadotropin-releasing hormone (GnRH) antagonists. One of
the GnRH, Elagolix also got approval by the Food and Drug Administration (FDA)
for operating endometriosis. Other medications were also recognized but the
majority these have only been assessed in early clinical trials or pre-clinical
studies. Additional extensive clinical research is needed to illustrate their
efficacy, safety and pharmacological characteristics in a better way.
Expert Opin Biol Ther.
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.
Fabio Barra et al.
Comments (0)